Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration. Regentis Biomaterials Ltd. (NYSE American: RGNT) is targeting this multi-billion-dollar market with Gelrin C, a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows.
Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C is a 10-minute procedure using an off-the-shelf hydrogel to support cartilage repair. With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is positioning Gelrin C as a practical regenerative solution for providers, payers and patients.
What begins as a localized cartilage defect can ultimately evolve into a significant clinical and economic challenge. Unlike many tissues in the body, articular cartilage has little ability to regenerate on its own, leaving untreated lesions vulnerable to progressive deterioration that may culminate in osteoarthritis (OA). The economic burden of knee OA in the U.S. is estimated at $15 billion annually, highlighting the need for interventions that can halt or slow disease progression.
Gelrin C is designed to address this gap by providing a simple, reproducible treatment that can be integrated into standard arthroscopic procedures. The hydrogel is implanted during a single surgery and provides a scaffold for the body’s own cells to regenerate cartilage tissue. This approach avoids the complexity and cost of cell-based therapies, which require cell harvesting, expansion and re-implantation.
The potential impact of Gelrin C extends beyond clinical outcomes. By treating cartilage defects early, the therapy could reduce the long-term costs associated with OA progression, including joint replacement surgeries, physical therapy and lost productivity. For payers, this represents an opportunity to manage healthcare spending more effectively while improving patient outcomes.
Regentis is currently advancing Gelrin C through clinical trials and regulatory processes. The company’s focus on a cell-free, off-the-shelf product aligns with the growing trend toward simpler, more scalable regenerative medicine solutions. If approved, Gelrin C could become a standard option for orthopedic surgeons treating cartilage defects.
For more information, visit the company’s newsroom at ibn.fm/RGNT.
This content was disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid marketing engagement with IBN. IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN. Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
